NEUROTECH INTERNATIONAL LIMITED

NEUROTECH INTERNATIONAL LIMITED (ASX: NTI)

Neurotech launches clinical program in Rett Syndrome
Phase II trial to investigate the use of NTI164 in females aged 5-20 with Rett Syndrome
Rett Syndrome is a rare neurological disorder with no cure and a market opportunity of over US$2 billion

2023-03-20 09:03:00

NTI164 shows strong safety and efficacy effects in ASD treatment over 52 weeks
Clinical benefits continue to show significant improvement over baseline measures
No serious adverse events recorded and no evidence of therapeutic tolerance with prolonged use

2023-03-17 09:45:00

Neurotech International Limited (NTI) has been informed that the first patient has received treatment in the Phase I/II clinical trial of NTI164 in children diagnosed with PANDAS/PANS.
The trial is designed to evaluate the efficacy, safety and tolerability of NTI164 for the treatment of paediatric neurological disorders.
Dr Thomas Duthy, Executive Director of Neurotech, congratulated Professor Dale and his clinical team at Children’s Hospital at Westmead for their involvement in the trial.

2023-02-16 11:27:00

Neurotech International Limited has been granted permission to extend the Phase I/II Autism Spectrum Disorder (ASD) clinical trial (NTIASD1) for an additional six months.
The extension is based on Neurotech's commitment to the paediatric patients and the request from the Paediatric Neurology Unit, Principal Investigator and families/caregivers.
Individual patients can continue to receive NTI164 for a total of 6 months over the 54 week treatment period.

2023-02-14 10:11:00

Neurotech International Limited has received Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) scheme clearance by the Therapeutic Goods Administration (TGA) to commence a Phase I/II clinical trial of NTI164 in children diagnosed with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PAN S).
Recruitment for the trial under the supervision of Co-Principal Investigator Professor Russell Dale is expected to commence during this quarter.
Dr Thomas Duthy, Executive Director of Neurotech, expressed appreciation for the timely approval.

2023-01-27 09:33:00

Neurotech International Limited announces that the US Food and Drug Administration has approved their request for a pre-Investigational New Drug Application meeting.
The purpose of the meeting is to seek FDA feedback in relation to the CMC package, non-clinical requirements, and the proposed clinical development program for NTI164 in Autism.
The meeting will be held on 15 March 2023 (US time).

2023-01-19 11:30:00